3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
20
Gastrointestinal
9
Head & Neck
5
Tumor-Agnostic
4
Genitourinary
2
Dermatologic
2
CNS
2
Breast
2
Sarcoma
1
Plasma cell
1
Lymphoid
1
Conditions
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Interventions
Dexamethasone
265
Lenalidomide
159
daratumumab
136
Bortezomib
112
pomalidomide
90
Calcium Dobesilate
86
Cyclophosphamide
85
carfilzomib
77
Specimen Handling
46
isatuximab
44
fludarabine
43
Biopsy
43
belantamab mafodotin
42
Magnetic Resonance Spectroscopy
38
dexamethasone acetate
34
dexamethasone 21-phosphate
34
auricularum
33
Melphalan
32
talquetamab
29
ixazomib
27
iberdomide
26
fludarabine phosphate
24
selinexor
22
elotuzumab
21
Whole-Body Irradiation
17
X-Rays
15
venetoclax
14
Mycophenolic Acid
13
tocilizumab
12
Stem Cell Transplantation
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Erlotinib Hydrochloride
×
Plasma cell
×
1 year
×
Clear all
NCT03297606
2026-03-27
CAPTUR
Canadian Cancer Trials Group
Phase 2
Recruiting
720 enrolled